Page last updated: 2024-11-07

n-acetylglucosaminylasparagine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-acetylglucosaminylasparagine: RN given refers to parent cpd; presence in urine characteristic of aspartylglucosaminuria; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N(4)-(beta-N-acetyl-D-glucosaminyl)-L-asparagine : An N(4)-glycosyl-L-asparagine having (beta-N-acetyl-D-glucosaminyl as the glycosyl component. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID123826
CHEBI ID17261
SCHEMBL ID243608
MeSH IDM0040022

Synonyms (64)

Synonym
2-acetamido-n-l-beta-aspartyl-2-deoxy-beta-d-glucopyranosylamine
2-acetamido-1-(beta-l-aspartamido)-1,2-dideoxy-beta-d-glucose
n(4)-(2-acetamido-2-deoxy-beta-d-glucopyranosyl)-l-asparagine
CHEBI:17261
2-acetamido-1-n-(4'-l-aspartyl)-2-deoxy-beta-d-glucopyranosylamine
n-acetylglucosaminylasparagine
beta-n-acetylglucosaminyl-l-asparagine
2776-93-4
2-acetamido-n(1)-l-beta-aspartyl-2-deoxy-beta-d-glucopyranosylamine
aadg
n(4)-(beta-n-acetyl-d-glucosaminyl)-l-asparagine
n4-(acetyl-beta-d-glucosaminyl)asparagine
n4-(beta-n-acetyl-d-glucosaminyl)-l-asparagine
C04540
1-beta-aspartyl-n-acetyl-d-glucosaminylamine
aspartylglucosamine
2-acetamido-n-[(3s)-3-azaniumyl-3-carboxylatopropanoyl]-2-deoxy-beta-d-glucopyranosylamine
(2s)-4-[[(2r,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoic acid
asparaginylglucosamine
l-asparagine, n-(2-(acetylamino)-2-deoxy-beta-d-glucopyranosyl)-
acetylglucosaminylasparagine
unii-q9odp9b8o5
q9odp9b8o5 ,
n(4)-(2-acetamido-2-deoxyglucopyranosyl)asparagine
aspartylglucosylamine
n-(2-acetylamino)-2-deoxy-beta-d-glucopyranosyl-l-asparagine
4-n-2-acetamido-2-deoxy-beta-d-glucopyranosyl-l-asparagine
aspartylglycosamine
SCHEMBL243608
W-202164
2-acetamido-2-deoxy-b-d-glucopyranosyl l-asparagine
h-asn(glcnac-beta-d)-oh
FD21203
(2s)-2-amino-3-{[(2r,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamoyl}propanoic acid
mfcd02259695
2-acetamido-1-b-(l-aspartamido)-1,2-dideoxy-d-glucose
beta-delta-glcnac-1->n-asn
n-(2-(acetylamino)-2-deoxy-beta-d-glucopyranosyl)l-asparagine
4-n-2-acetamido-2-deoxy-beta-delta-glucopyranosyl-l-asparagine
b-d-glcnac-1->n-asn
(n-gamma-(2-acetamido-2-deoxy-beta-d-gluco-pyranosyl)-l-asparagine
n-(2-acetylamino)-2-deoxy-beta-delta-glucopyranosyl-l-asparagine
(n-gamma-(2-acetamido-2-deoxy-beta-delta-gluco-pyranosyl)-l-asparagine
n-(2-(acetylamino)-2-deoxy-beta-delta-glucopyranosyl)l-asparagine
(n-g-(2-acetamido-2-deoxy-b-d-gluco-pyranosyl)-l-asparagine
n(4)-(acetyl-beta-d-glucosaminyl)asparagine
beta-d-glcnac-1->n-asn
2-acetamido-1-n-(4'-l-aspartyl)-2-deoxy-beta-delta-glucopyranosylamine
2-acetamido-1-beta-(l-aspartamido)-1,2-dideoxy-d-glucose
h-asn(glcnac-b-d)-oh
2-acetamido-1-beta-(l-aspartamido)-1,2-dideoxy-delta-glucose
h-asn(glcnac--d)-oh
aadg;aspartylglucosamine;n--(2-acetamido-2-deoxy--d-gluco-pyranosyl)-l-asparagine
Q4807723
h-asn(|a-d-glcnac)-oh
2-acetamido-2-deoxy-beta-d-glucopyranosyl l-asparagine
n-(2-(acetylamino)-2-deoxy-.beta.-d-glucopyranosyl)-l-asparagine
asparagine-n-acetyl-.beta.-d-glucosamine conjugate
h-asn(glcnac-.beta.-d)-oh
asparagine, n-(2-acetamido-2-deoxy-.beta.-d-glucopyranosyl)-
l-asparagine, n-(2-(acetylamino)-2-deoxy-.beta.-d-glucopyranosyl)-
DTXSID401027514
HY-N9446
CS-0173272

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In the current work, ERT of AGU mice was initiated at the age of 1 week with three different dosage schedules of recombinant glycosylasparaginase."( Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice.
Dunder, U; Kelo, E; Mononen, I; Valtonen, P, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
glucosaminylamineA member of the class of glucosamines that is 2-amino-2-deoxyglucose in which the anomeric hydroxy group has been replaced by an additional amino group.
N(4)-glycosyl-L-asparagine
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (110)

TimeframeStudies, This Drug (%)All Drugs %
pre-199041 (37.27)18.7374
1990's53 (48.18)18.2507
2000's12 (10.91)29.6817
2010's3 (2.73)24.3611
2020's1 (0.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.66 (24.57)
Research Supply Index4.72 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews12 (10.81%)6.00%
Case Studies22 (19.82%)4.05%
Observational0 (0.00%)0.25%
Other77 (69.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]